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SUmlTlary 
Interleukin-12 (IL-12)  induces differentiation of T  helper 1 (Thl) cells, primarily through its 
ability to prime T  cells for high interferon-~/ (IFN-~)  production. We now report that the 
presence of IL-12 during the first several days of in vitro clonal expansion in bruiting dilution 
cultures of polyclonally stimulated human peripheral blood CD4 + and CD8 + T  cells also in- 
duces stable priming for high IL-10 production. This effect was demonstrated with T cells from 
both healthy donors and HIV(+) patients. Priming for IL-4 production, which requires IL-4, 
was maximum in cultures containing both IL-12 and IL-4. IL-4 modestly inhibited the IL-12- 
induced priming for IFN-% but almost completely suppressed  the priming for IL-10 produc- 
tion. A proportion of the clones generated from memory CD45RO + cells, but not those gen- 
erated from naive CD451KO-  CD4 + T  cells, produced some combinations of IFN-% IL-10, 
and IL-4 even in the absence of IL-12 and IL-4, suggesting in vivo cytokine priming; virtually 
all CD4 § clones generated from either CD45RO(-)  or (+) cells, however, produced high lev- 
els of both IFN-~/and IL-10 when IL-12 was present during expansion. These results indicate 
that each Thl-type (IFN-~/)  and Th2-type  (IL-4 and IL-10)  cytokine gene is independently 
regulated in human T cells and that the dichotomy between T cells with the cytokine produc- 
tion pattern of Thl and Th2 cells is not due to a direct differentiation-inducing effect of im- 
munoregulatory cytokines, but rather to secondary selective mechanisms. Particular combina- 
tions ofcytokines induce a predominant generation ofT cell clones with anomalous patterns of 
cytokine production (e.g.,  IFN-~ and IL-4 or IFN-~/ and IL-10) that can also be found in a 
proportion of fresh peripheral blood T  cells with "memory" phenotype or clones generated 
from them and that may identify novel Th subsets with iminunoregulatory functions. 
T 
he immune response to infectious agents and to nomi- 
nal antigens is often characterized by a dominance of 
either cell-mediated or humoral-type effector mechanisms 
(1), which has been attributed to a dichotomy in the cyto- 
kine production pattern of T  helper (Th)  CD4 + cells (2). 
Two classes of Th cells have been described: Thl cells, which 
produce interleukin-2 (IL-2), interferon-~/(IFN-~/) and lym- 
photoxin (LT) and favor cell-mediated immunity, delayed- 
type hypersensitivity, macrophage activation, and produc- 
6on of opsonizing antibodies;  and Th2 cells, which produce 
IL-4, IL-5, IL-6, IL-10, and favor humoral responses,  pro- 
duction of IgE and IgA, and activation of eosinophils and 
basophils.  The differentiation of Th cells toward a Thl  or 
Th2  phenotype occurs  early during an immune response 
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and is  influenced by many interrelated factors,  including 
the nature and the concentration of the antigen, the ana- 
tomical locahzation of the immune response, the nature of 
the antigen-presenting cells  (APC),  and the cytokine mi- 
lieu at the site of the immune response (3). IL-4, produced 
by T  cell subsets and possibly basophils,  appears  to be the 
most important cytokine responsible for Th2 cell genera- 
tion  (4), whereas  IL-12,  produced  by  macrophages  and 
professional APC  such  as  dendritic  cells  and  Langerhans 
cells (5-8), is required for effective Thl cell generation (9- 
12). IL-12 acts at three different levels in favoring a Thl re- 
sponse:  (a)  it acts as a proinflammatory cytokine inducing 
IFN-~/from T and NK cells within a few hours after infec- 
tion, and through IFN-~/  it induces activation of phago- 
cytic cells for bacteriocidal activity and also for enhanced 
production of cytokines, including IL-12 itself (6,  13-15); 
(b) in the first few days of an immune response, IL-12 and 
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favor differentiation  and  proliferation  of cells with  a  Thl 
phenotype  (9--12);  (c)  once  differentiated  Thl  are  gener- 
ated,  IL-12  is  required  for  optimal  cytokine  production 
and, in certain cases, proliferation of Thl  cells (16). One of 
the central mechanisms by which IL-12 induces differentia- 
tion of Thl  cells is its ability to prime T  cells during clonal 
expansion for high IFN-'y production  (17-19).  This prim- 
ing effect oflL-12 is stable, and T  cell clones originally ex- 
panded  in  the  presence  of IL-12  maintain  the  ability  to 
produce  high IFN-~/levels upon restimulation  even when 
cultured for at least several weeks in vitro in the absence of 
IL-12 (17). However, IL-12 when present during restimu- 
lation  also  enhances  IFN-~/  production  from  established 
Thl  clones (16,  17) and transiently induces low level IFN- 
",/ production  from  established  Th2  clones  (17,  20).  Like 
CD4 +  T  cells,  CD8 +  T  cells also  display either  a  Thl  or 
Th2  phenotype  (17,  21,  22),  and  IL-12 induces  a priming 
for high IFN-',/production in both CD4 + and CD8 + T  cells 
(17,  18). 
Although  the expression of Thl-type  and Th2-type cy- 
tokines  was  initially  considered  to  be  mutually  exclusive, 
Th cells expressing both Thl  and Th2  cytokines  (referred 
to as Th0 cells) have been identified both during differenti- 
ation  of Th cells  (23)  and in terminally  differentiated  cells 
(24).  Indeed,  evidence for a stochastic  acquisition  of cyto- 
kine profile, suggesting independent  regulation  of each cy- 
tokine gene, was obtained during a mouse Th2 response to 
keyhole limpet hemocyanin (KLH) (25)  and in human pe- 
ripheral blood memory CD4 +  T  cells  (26,  27).  Our find- 
ings  that  IL-12  has  a  potent  priming  effect  on  human  T 
cells for high IFN-3~ production, but no direct effect on IL-4 
production by T  cell clones, also strongly suggested an in- 
dependent  regulation  of IFN-~/ and  IL-4 gene  expression 
(17).  IL-10, like IL-4, was thought  to be produced  exclu- 
sively by Th2  cells in the  mouse  (2),  but it has since been 
reported that both mouse and human IL-10-producing cells 
can coexpress either IL-4 or IFN-~/(28, 29). 
In this paper, we analyzed the effect oflL-12 on the ex- 
pression oflL-10 in human CD4 + and CD8 + T  cell clones. 
We  find that  IL-12 when  present  in  the  limiting  dilution 
cultures  in  the  first few  days of clonal  expansion,  primes 
CD4 + and CD8 + T  cell clones for high production of both 
IFN-~/and  IL-10.  IL-12 does not prime for IL-4 produc- 
tion, which requires the presence of IL-4 during clonal ex- 
pansion; however, priming for IL-4 production  is maximal 
in  cultures  containing  both  IL-12  and  IL-4.  IL-4  has  a 
modest inhibitory effect on the IL-12-induced priming for 
IFN-~/  production,  but  almost  completely  suppresses  the 
priming for IL-10 production. 
Materials and Methods 
Reagents.  Phytohemagglufinin  (PHA) was purchased from Grand 
Island Biological Co. (Grand Island,  NY). Dermatophagoides ptero- 
nyssinus group I (Der p I) was kindly provided from Lofarma A1- 
lergeni (Milan,  Italy), and 12-0-tetradecanoyl-phorbol-13-acetate 
(TPA) I was from Sigma Chemical Co. (St. Louis, MO). Anti-CD3, 
anti-CD4, and anti-CD8 mAbs were purchased from Ortho Phar- 
maceuticals  (R.aritan, NJ) and Becton-Dickinson (Mountain View, 
CA), or produced from cells obtained from American Type Cul- 
ture Collection  (ATCC,  tkockville, MD).  Human recombinant 
IL-2 (rIL-2) was a gift of Eurocetus  (Milan, Italy)  and of Dr. T. 
Taguchi (Osaka University, Osaka, Japan). Human rlL-12 (CHO- 
cell  derived) was provided by Dr.  Stan Wolf (Genetics Institute 
Inc., Cambridge, MA).  Human rIL-4 was purchased from Gen- 
zyme (Cambridge, MA) and had a specific activity of 107 U/mg. 
Human  rIFN-'y (7  ￿  107  U/mg)  was  provided  by Dr.  H.M. 
Shepard (Genentech Inc., South San Francisco,  CA). 
Subjects.  Peripheral blood mononuclear cells  (PBMC)  were 
obtained by Ficoll-Hypaque gradient separation from peripheral 
blood of healthy volunteers and human immunodeficiency virus 
type 1 (HIV-1)-infected individuals,  recruited from the Immuno- 
deficiency Program of the Hospital of the University of Pennsyl- 
vania. CD4 + lymphocyte counts were obtained on the same day 
that patients' blood was obtained for use in  this  study.  Patients 
were  categorized according to  the  Centers for Disease Control 
criteria  on  the  basis  of CD4 +  lymphocyte  number  and  HIV- 
related symptomatology and complications (30). 
Generation of CD4 + and CD8 + T  Cell Clones.  T  cell  clones 
were  generated from PBMC  by limiting dilution  (17,  31).  0.5 
PBMC/well were seeded in 96-well round-bottom tissue culture 
plates  in 200  p,1 of RPMI-1640 medium with  10% FCS  in the 
presence of 5 p,g/ml PHA, "y-irradiated  (50 Gy) autologous (for 
cloning of healthy  donor  T  cells)  or allogeneic  (for cloning  of 
HIV(+)  patients'  T  cells)  PBMC  (2.5  X  104  cell/well)  and 
P,.PMI-8866 B  lymphoblastoid cells (104 cells/well) in the pres- 
ence of IL-12 (2.5 ng/ml), IL-4 (50 U/ml), neutralizing  anti-IL-12 
mAb C8.6 (ascites, 1:400, sufficient to completely neutralize more 
than  10  ng/ml of IL-I2, a level higher  than  that possibly pro- 
duced by the feeder cells) (6), anti-IL-4 neutralizing  antibodies 4F2 
and 5A4 (32), a combination of cytokines and antibodies or cul- 
ture medium.  In some experiments,  limiting dilution  cloning was 
performed  in  U-bottom  plates  coated  with  anti-CD3  mAb 
(OKT3, 5  p,g/ml in carbonate buffer, pH 9.5)  instead of in the 
presence of PHA. After 3 days,  IL-2 (50 U/ml, final concentra- 
tion) was added to all cultures by replenishing half of the medium. 
After 1 wk,  irradiated  PBMC  (5  ￿  103/well)  and  RPMI-8866 
(104/well)  as feeder cells were added again; cells were maintained 
in culture with IL-2 and fed and split as required with the original 
combination of antibodies and/or cytokines maintained through 
the culture period, unless otherwise indicated. Cloning efficiency 
was calculated for CD4 + or CD8 + by Poisson distribution as de- 
scribed (17, 31, 33);  only wells containing a sufficient T cell num- 
ber to allow determination of both surface phenotype and cytokine 
profile were considered positive, The proportion of CD4 + and 
CD8 + T cells in the plated PBMC was taken into account in cal- 
culating the number of cells from either subset plated per well. 
Surface Phenotype of T  Cells.  The phenotype of PBMC and T 
cell clones was examined by immunofluorescence (flow cytome- 
try) using FITC-conjugated anti-CD3,  anti-CD4,  and anti-CD8 
rnAbs as described (17). 
Sorting of CD45RO + and RO-  T  Cells.  PBMC  were  stained 
by indirect  immunofluorescence  using the anti-CD45RO  mAb 
Leu 45R.O  (Becton  Dickinson)  and  FITC  goat anti-mouse  Ig 
(Becton Dickinson). Cells were sorted using a Coulter Elite cell 
1Abbreviation used in this paper: TPA, 12-0-tetradecanoyl-phorbol-13-ace- 
tate. 
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CD45R.O +.  After  sorting,  purified  CD45RO-  cells were con- 
taminated with  1.2% CD45RO + ceils and purified  CD45R_O + 
cells were contaminated  with 2% CD45RO- cells. Immediately 
after  sorting,  T  cells were  cloned by limiting  dilution,  as  de- 
scribed above. 
Induction of Cytokine Production by T Cell Clones.  To induce cyto- 
kine production, T cell clones were resuspended in complete me- 
dium to a concentration of approximately  106/ml and stimulated 
for 24 h with soluble anti-CD3 mAb (OKT3, ascites 1:10,000) and 
TPA (10 ng/ml). Cell-free culture supematants were collected and 
stored in aliquots at -70~  until used. 
Quantitation of lFN-% IL-4, and IL- I O.  IFN-"/  was  quantitated 
in T  cell clone supernatants  by radioimmunoassay  (RIA) using 
mAbs B133.1 and B133.5  (34); IL-4 was quantitated  by RIA us- 
ing antibodies 4F2 and 5A4 (32), kindly provided by Dr. Lucien 
Aarden  (Central Laboratory  of the Netherlands  Red Cross, Am- 
sterdam);  IL-10 was  quantitated  by RIA using  antibodies JE53 
9D7 and  12G8, kindly provided by Dr. Anne O'Garra (DNAX, 
Palo  Alto,  CA).  Recombinant human IFN-% IL-4, and IL-10 
were used as reference standards. 
Statistical Analysis.  The  statistical significance for the  differ- 
ence in cytokine production by the group of clones cultured  in 
the different conditions  was evaluated by student's  t test; signifi- 
cant and not significant, when not specifically indicated,  refer to 
P <0.05 and P >0.05, respectively. 
Results 
IL- 12 Primes CD4 + and CD8 + Clones for IL- 10 Production 
and IL-4 Inhibits Such Priming.  Freshly  isolated  peripheral 
blood lymphocytes (PBL)  from two donors were cloned by 
limiting dilution in the presence of feeder cells,  IL-2, and 
PHA or anti-CD3 antibodies bound to plastic.  IL-12 and/or 
IL-4 was also added to some of the plates. When IL-12 or 
IL-4 was not added,  the respective neutralizing antibodies 
were added to block endogenous cytokines. After 4 wk of 
culture,  clones were washed, stimulated with soluble anti- 
CD3 antibodies and TPA for 18 h, and cytokine produc- 
tion in the supematant was evaluated by ILIA (Fig.  1).  As 
previously reported (17-19),  the presence of IL-12 during 
cloning induced a several-fold increase in the ability of both 
CD4 § and CD8 + clones to produce IFN-~/, whereas it had 
a little and non-significant effect on IL-4 production.  The 
addition of IL-4, either alone or with IL-12, had no signif- 
icant effect on the production of IL-4, but partially inhib- 
ited the priming for IFN-'y production (Fig.  1). The failure 
in these experiments to identify a requirement for IL-4 in 
the generation of IL-4 producing cells was likely due to the 
presence within the unfractionated PBL or memory T  cells 
which,  as described below, generate clones with high and 
variable ability to produce IL-4 even when expanded in the 
absence of IL-4.  In addition  to priming the T  cell clones 
for IFN-~/production,  IL-12, present during cloning,  also 
primed them for high IL-10 production, an effect observed 
in both cloning conditions  (PHA or anti-CD3)  and with 
both CD4 + and CD8 § clones (Fig. 1). IL-4 alone had no sig- 
nificant effect on the abihty of the clones to produce IL-10, 
but significantly and almost completely inhibited the prim- 
ing effect oflL-12 on IL-10 production. 
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The  ability  of IL-12  or  anti-IL-12  antibodies  present 
during bruiting dilution cloning to prime CD4 + and CD8 + 
clones for IL-10 production was also observed in PBL from 
five other healthy individuals and 10 HIV(+) patients at vari- 
ous stages of the disease;  analysis  of all CD4 + and all CD8 + 
clones from either healthy donors (Fig. 2 A) or HIV(+) pa- 
tients (Fig.  2 B) revealed significant IL-10 production after 
IL-12 priming  (P  =  0.027  for CD4 +  cells  from HIV(+) 
patients; P ~0.001 in all other groups). In several of the ex- 
periments  represented  in  Fig.  2,  IL-12 was  present  only 
during the first 2 wk of the 4-wk cloning period. 
Clones Derived from Naive and Memory  CD4 + T  Cells Are 
Differentially Affected  by IL-12.  Because of the high variabil- 
ity in cytokine production by clones derived from total PBL, 
even when cultured in the absence of added cytokines, we 
separately cloned CD4 § cells with a memory (CD45RO +) 
or naive phenotype (CD45tLO-)  (35)  (Figs.  3 and 4). The 
large majority of CD4 + clones generated from CD45RO- 
cells in the presence of neutralizing antibodies to IL-12 and 
IL-4 produced negligible amounts oflFN-% IL-10, or IL-4 
(Fig.  4). By contrast,  approximately half of the clones de- 
rived from CD45RO +  cells  produced  IFN-~/ and  IL-10, 
even when  expanded  in  the  presence  of anti-IL-12  anti- 
bodies,  and IL-4 even when expanded in the presence of 
anti-IL-4 (Fig. 3). When cultured in the presence oflL-12, 
all  clones produced  high levels of IFN-~/ and  IL-10, and 
when cultured in the presence of IL-4, most although not 
all the clones produced high levels of IL-4. However, the 
differential ability of the clones to produce the various cy- 
tokines  depending  on  the  culture  conditions  was  much 
more obvious in the clones derived from CD45RO-  cells 
(Figs.  3  and 4).  These clones expanded in the presence of 
anti-IL-12 produced  very low levels  of IFN-~/  or  IL-10, 
which on average were increased 125-fold and 29-fold, re- 
spectively, in the clones expanded in the presence of IL-12. 
The production of IL-10 by the different clones was more 
variable than that of IFN-% as clearly shown by the SE in 
Fig.  4.  Thus,  whereas IL-12 was an absolute requirement 
for  high  production  of  IFN-%  a  minor  proportion  of 
clones produced moderate to high IL-10 even when cul- 
tured in the absence of IL-12. IL-4 was required for prim- 
ing  CD45RO-  cells  for  IL-4  production,  but  endoge- 
nously produced  IL-4 in  the  cultures  (most likely by the 
irradiated  feeder  cells)  was  sufficient,  because  addition  of 
neutralizing antibodies to IL-4 to the cultures blocked IL-4 
production by the  clones, whereas addition  of exogenous 
IL-4 only modestly increased IL-4 production as compared 
to that by clones generated without either IL-4 or anti-IL-4 
antibodies (Fig.  4). Interestingly, the highest production of 
IL-4 was reproducibly observed in clones generated in the 
presence of both IL-12 and IL-4, although all these clones 
also  produced  high  levels  of IFN-%  In  the  presence  of 
added IL-4, but not IL-12, approximately a quarter of the 
clones have a Th2 phenotype (i.e., they produced moder- 
ate to high amounts of  both IL-4 and IL-10, but not IFN-~/). 
The presence oflL-4 during the expansion of the clones, as 
with  total  PBL  cloning  (Fig.  1),  modestly  decreased  the 
priming effect of IL-12 for IFN-~/ production,  but almost 2.51  2.0 
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Figure  1.  IL-12 primes CD4 + 
and CD8 + T cell clones for pro- 
duction  of  IFN-~/  and  IL-10. 
PBL  from  one  donor  were 
cloned in  the presence  of PHA 
and  from another  donor  in  the 
presence  of plastic-bound  anti- 
CD3 antibodies,  and  the  clones 
were  expanded  in  the  presence 
of feeder cells (irradiated autolo- 
gous  PBMC  and  RPMI-8866 
cell  line)  and  the  indicated  cy- 
tokines for 4 wk.  IL-2 was used 
at 50 U/ml, IL-12 at 2.5 ng/m], 
and  IL-4  at  50  U/ml.  When 
IL-12 or IL-4 was not added, the 
respective neutralizing antibodies 
were used  to block endogenous 
cytokines.  Clonal  growth  effi- 
ciency  was  on  average  ~50%, 
and lower (20-30%)  when anti- 
IL-4  was  present.  Clones  were 
then washed in medium without 
cytokines,  stimulated  for  t8  h 
with soluble  anti-CD3 antibod- 
ies  and  TPA  as  described  m 
Experimental  Procedures,  and 
cytokine  production  in  the  su- 
pernatant  was  quantitated  by 
P, IA.  Data  represents  mean  -+ 
SE of all clones analyzed. 
completely  suppressed  the  IL-12  priming  effect  for  IL-10 
production  (Fig. 4). 
The Priming Effect of lL-12 for IL-10 and IFN- y Production 
Is Not Mediated by IFN-T.  We investigated whether IFN-"/ 
induced  by IL-12 plays a  role in the priming  of the T  cell 
clones for IFN-3' and IL-10 production and whether IFN-y 
could replace  IL-12 in inducing such  a priming. As shown 
in Table  1, neutralizing anti-IFN-'/antibodies did not pre- 
vent  the  IL-12-induced  priming  for  IFN-3, production  in 
clones originated from either CD4 +  CD45RO-  or CD8 + 
CD45RO-  T  cells,  and  exogenous  recombinant  IFN-y 
added to the cultures in the absence oflL-12, could not in- 
duce priming.  In the case of priming for IL-10 production, 
anti-IFN-y  antibodies  partially  but  significantly  (P <0.05) 
decreased  it in  CD4 +  T  cell clones,  but  have no  effect in 
CD8 +  T  cell clones; in both  types of clones,  IFN-y  could 
not replace  IL-12 to  induce  IL-10 priming.  No  significant 
difference  was  observed  in  all  these  experimental  condi- 
tions for IL-4 production by the clones. 
The Priming Effect of I  L-12for IL-10 Production Is Stable and 
Occurs in the First Few Days of Clonal Expansion.  The  prim- 
ing effect of IL-12  on  IL-10  production  is  stable,  because 
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Figure 2.  Production oflFN-~/and IL-10 by CD4 + and CD8 + clones 
from 7 different healthy patients (A) and 10 HIV(+) patients (/3) gener- 
ated by limiting dilution in the presence of neutralizing anti-IL-12 anti- 
bodies (C8.6, ascites, 1:400) or recombinant human IL-12 (2.5 ng/ml). 
The PBMC used as irradiated feeder cells were autologous for the cloning 
of healthy donors' PBL and from allogeneic healthy donors for the clon- 
ing of HIV(+) patients' PBL. For several of the donors, IL-12 was added 
only in the first 2 wk of cultures. After 5 weeks of culture, the CD4 + 
(bottom) and CD8 § clones (top) were washed and stimulated with anti- 
CD3 and TPA for 18 h. Cytokines were measured in the cell-free super- 
natant fluids by RIA. Each symbol represents the cytokine production by 
one individual clone. The results in A are cumulative of the 7 healthy 
donors; the results in B are from the  10 HIV(+) patients. IL-12 treat- 
ment significantly increased the ability of the clones to produce IFN-'y 
(P <0.001) and IL-10 (P =  0.027 for CD4 + cells from HIV(+) patients, 
P ~<0.001 in all other groups). 
addition of neutralizing anti-IL-12 antibodies after 1 wk of 
limiting dilution culture in the presence of IL-12 only par- 
tially decreased and  after 2  wk  did not  affect the priming 
for both IFN-~ and IL-10 production (results not shown). 
To determine when during clonal expansion IL-12 induces 
priming  for  IFN-~/  and  IL-10  production,  low  levels  of 
neutralizing anti-IL-12 antibodies were  added at the time 
of limiting dilution to prevent the effect of endogenously 
produced IL-12, and IL-12 at concentrations able to over- 
come the effect of the neutralizing antibodies was added at 
different times of culture. The priming effect was observed 
when IL-12 was added at day 0  or 3, but not when added 
at day 7 or later (Fig. 5). 
Discussion 
Accumulating evidence from in vivo and in vitro exper- 
imental systems supports the conclusion that IL-12 not only 
promotes Thl-type immune responses, but is also required 
in vivo for optimal Thl  responses  (8-10,  36).  In all these 
experimental systems,  IL-12 not  only induced an increase 
in  IFN-~/ production,  but  also very efficiently suppressed 
the  production  of IL-4.  However,  the  in  vivo  studies  or 
the  in vitro  analysis based on  the  effect of IL-12  on  bulk 
polyclonal T  cell cultures did not distinguish between a di- 
rect effect of IL-12 on the differentiation of the Th clones, 
or an indirect effect favoring preferential expansion of Thl 
cells or inhibition of Th2  cell growth.  To  distinguish be- 
tween direct effects on Th cell differentiation and selective 
effects, we  (17)  analyzed the effect of IL-12 on  the  cyto- 
kine production of human  CD4 §  and  CD8 +  T  cells in  a 
limiting dilution  cloning system  which  allows  the  clonal 
expansion  of almost  every  single  T  cell  from  peripheral 
blood. Because of the high clonal efficiency and the seed- 
ing of less than one cell per well, this experimental system 
allowed us  to  test direct differentiative effects of IL-12  at 
the clonaltevel. Whereas IL-12 induced a powerful prim- 
ing for high IFN-~/production in every single clone ana- 
lyzed, it had no significant effect on the ability of the clones 
to  produce  IL-4  (17).  Thus,  it  was  concluded  that  the 
priming for high IFN-~/production is a  direct differentia- 
tion-inducing effect of IL-12, while the inhibition of IL-4 
production  may  involve  preferential  expansion  of  Thl 
cells, due perhaps to the lack of functional IL-12 receptors 
on  Th2  cells (37,  38),  or a  selective growth  inhibition of 
Th2 cells by IFN-~/(39), most likely due to the downmod- 
ulation of the IFN-~/receptor 13 chain in Thl cells (38, 40). 
There is relatively little information on the effect oflL-12 
on T  cell production oflL-10, but studies with bulk T  cell 
cultures from atopic patients stimulated in vitro with aller- 
gen  have  shown  that  production  of both  Th2  cytokines, 
IL-4 and IL-10, is inhibited if lL-12 is added to the cultures 
(41). We have been able to reproduce these results both in 
bulk  cultures  or analyzing antigen-specific clones  derived 
from these cultures (our unpublished results). However, in 
vivo treatment with IL-12 has been reported to result in a 
dramatic increase in both IFN-~/mRNA  and IL-10 mRNA 
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Figure  3.  Cytokine  production  by  CD4  +  clones  generated  from 
CD45ILO- and CD45ILO + T  cells. PBL were sorted into CD45RO- 
and ILO + subsets and cloned by limiting dilution in the presence ofanti- 
IL-12 antibody  (C8.6, ascites, 1:400) and human recombinant IL-4 (50 
U/ml) or human recombinant IL-12 (2.5 ng/ml) and anti-IL-4 antibodies 
(4F2 and 5A4, ascites, 1:100). After 4 wk, clones were washed, incubated 
for 24 h in medium containing only IL-2 (50 U/ml), washed again, and 
stimulated with anti-CD3 and TPA; the cell-free supernatant fluid was 
collected after 18-h stimulation and cytokines were quantitated by ILIA. 
Each dot represents a single CD4  + clone. This experiment is representa- 
tive of three  performed  with superimposable results. A, CD45ILO(-), 
IL 4, anti-IL-12;  A, CD45ILO(-), IL-12, anti-IL-4;  ￿9  CD45ILO(+), 
IL 4, anti-IL-12; O, CD45RO(+), IL-t2, anti-IL-4. 
(42),  although  the  nature of the  cells accumulating IL-10 
mRNA,  either T  cells or macrophages, was not investigated. 
Our  present  data  show  that  the  presence  of IL-12  in 
vitro during limiting dilution cloning of human CD4 +  or 
CD8 +  T  cells results in an efficient priming of the  clones 
for high production of both IFN-y  and IL-10.  This result 
was observed with both anti-CD3 or PHA stimulation and 
with PBL from both healthy donors and HIV(+)  patients, 
from  early to  very advanced stages  of HIV  disease.  These 
findings  are  consistent  with  the  observation  that  T  cells 
from  HIV  patients  are  fully responsive  to  IL-12  (18,  43, 
44),  although their phagocytic cells and APC might be de- 
fective in IL-12 production (45, 46). 
The high variability in production of cytokines observed 
in human CD4 +  T  cell clones expanded in the absence of 
exogenous IL-12 and IL-4 or in the presence of neutraliz- 
ing  antibodies  against  these  two  cytokines  suggests  that 
some of the ceils were already primed in vivo for cytokine 
production. The cloning of sorted CD45R.O-  naive CD4 + 
cells  and  CD45RO  +  memory  CD4 +  cells  supported  this 
interpretation.  A  high proportion  of the  clones generated 
in the presence of neutralizing antibodies to IL-12 and IL-4 
produced one or a combination of IFN-',/, IL-4 and IL-10, 
with a pattern of production that was not always consistent 
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Figure 4.  Cytokine production by CD4 + clones generated from sorted 
CD45ILO-  cells. CD45RO-  cells were  cloned by  limiting dilution 
(PHA stimulation) in the presence or absence of IL-12 (2.5 ng/ml), IL-4 
(50 U/ml), anti-IL-12 neutralizing mAb (C8.6, ascites, 1:400), anti-IL-4 
neutralizing rnAb (4F2 and 5A4, ascites, 1:100), or combinations thereof. 
After 4 wk, the clones were washed, incubated for 24 h in medium con- 
taining IL-2 (50 U/ml) only, washed again, and then stimulated for 18 h 
with soluble anti-CD3 antibodies and TPA; cytokines were measured in 
the cell-flee supernatant fluid by ILIA. The graphs report the mean -+ SE 
of the cytokine production of all clones analyzed in each cloning condi- 
tion. Arbitrary threshold ofcytokine production (broken lines) are drawn 
to facilitate the analysis  of the results. Clonal efficiency was "-'50%, except 
that in the cultures in the presence of anti-IL-4, where the efficiency was 
20-30%.  Data from this experiment  are representative of three  cloning 
experiments with similar results, except  the  cloning in the presence of 
both anti-IL-4 and anti-IL-12,  which  generated a sufficient number of 
clones for analysis in only two experiments, m  (anti-lL-12  +  anti-IL-4) 
(n =  11); O, (anti-IL-12) (n =  36); A, IL-12 (anti IL-4) (n = 26); A, IL- 
l2 (n = 43); D, lL-12 +  IL-4 (n =  51); O, IL-4 (anti-lL-12) (n =  41). 
with  the  classical paradigm  of Thl  and  Th2  cells.  When 
CD45P,.O-  cells were  cloned in the  same  conditions, the 
clones produced  only negligible amounts of the  three  cy- 
tokines. However, in both populations, the presence of IL-12 
during cloning endowed virtually all clones with the ability 
to  produce  high  levels  of IFN-y  and  IL-10.  These  data 
confirm our previous observations that IL-12 can induce a 
high IFN-y-producing Thl  phenotype not only in naive T 
cells,  but  also  in  memory  T  cells,  in  response  to  either 
polyclonal activation or specific recall antigens (9,  17). Sur- 
prisingly, the same observation held true for the priming of 
IL-10 production in a limiting dilution condition. 
Added IL-4 or endogenously produced IL-4 was neces- 
sary in the limiting dilution culture to prime T  cell clones 
generated from CD45RO-  cells for IL-4 production, whereas 
approximately half of the clones generated from CD45RO + 
cells produced IL-4 even when expanded in the absence of 
IL-4. Because of this high variability in IL-4 production in 
memory T  cells, the requirement for IL-4 in the generation 
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Figure 5.  IL-12  induces  priming for high IFN-~/and IL-10 production 
in CD4 + clones only when added during the first few days of clonal ex- 
pansion. PBL from normal donors were cloned by limiting dilution (PHA 
stimulation) in the presence of medium or neutralizing  anti-IL-12 anti- 
bodies (C8.6, ascites, 1:1,000); in different plates, IL-12 (5 ng/ml) was 
then added at day 0, 3, 7, 10, and 14 after limiting dilution cloning. This 
concentration  of IL-12 overcame the inhibitory effect of the low concen- 
trations of anti-IL-12 antibodies,  as determined empirically.  After 5 wk, 
clones were washed and restimnlated  with soluble  anti-CD3 and TPA for 
18 h. Cytokines were measured by RIA in cell-flee supematant fluids. 
Bars show mean + SE of all clones analyzed  in each condition of culture. 
This experiment is representative of three cloning experiments with su- 
perimposable results for both CD4  + and CD8  + clones. 
of IL-4 producing cells could not be demonstrated in CD4 + 
CD45RO +  cells  (Fig.  3)  or  unfractionated PBL  (Fig.  1). 
Although IL-12 is a major and probably necessary inducer 
of a  Thl  response,  in several  experimental conditions, it 
also  potentiated IL-4 production and the  development of 
Th2 cells from naive CD4 + murine T  cells (47)  and from 
neonatal CD4 + human T  cells (48), and potentiated a Th2 
response  to  Schistosoma  mansoni  in IFN-',/ knockout mice 
(49).  Our present data  show that IL-12 does  not prevent 
IL-4 production from CD4 + clones derived from limiting 
dilutions of naive adult peripheral blood CD45RO-  cells 
and,  in fact,  significantly enhances the  ability of IL-4  to 
prime the clones for high IL-4 production, thus extending 
the previously published results (47-49)  by demonstrating 
that  IL-12  enhances IL-4 production at  the  single clonal 
level via a differentiation effect. Furthermore, when T  cells 
were cloned in the simultaneous presence oflL-12 and IL-4, 
the  IFN-"/ priming effect  of IL-12 was  only partially and 
often not significantly  inhibited by IL-4, whereas the prim- 
ing  for  IL-10  production  was  reproducibly  and  almost 
completely blocked by IL-4.  Thus,  paradoxically, IL-4 is 
more potent in inhibiting priming of Th cells for produc- 
tion of a Th2-type cytokine than for the typical Thl-type 
cytokine, IFN-'y. 
Several authors have reported the requirement of IFN-~/ 
production for the induction of Thl  response in vivo and 
in vitro (11, 49-52); however, this role for IFN-~/was not 
confirmed in other murine studies (53, 54) and in none of 
the human studies (9, 41, 48). In the present study, neutral- 
izing anti-IFN-~/ antibodies  did  not  prevent  the  IL-12- 
induced priming for IFN-~ production and only partially 
decreased  priming for  IL-10 in  CD4 +  but not in CD8 + 
clones. Recombinant IFN-~/could not replace IL-12 in the 
priming for either IFN-~ or IL-10 production. 
We  have  previously shown  that  the  priming for  high 
IFN-~/-induced production induced by IL-12 is stable and 
that  if IL-12  is  present in  the  first  2  wk  of culture,  the 
clones can be cultured for at least 3 more weeks in the ab- 
sence of IL-12 and maintain their ability to produce high 
levels of IFN-"/ (17,  18).  For induction of IFN-~/produc- 
tion in the clones, IL-12 needs not be present during stim- 
Table 1.  Role of lFN-'y in IL-12-mediated  Priming of  Human CD4 + and CD8 + T  Cell Clones for IFN-'y and IL-IO Production 
Cells*  Cloning conditionsr  Number of clones  IFN-',/  IL-10  IL-4 
CD4 + CD45RO- 
CD8 + CD45RO- 
U/ml  pg/ml  pg/ml 
anti-IL-12  17  132 --- 57~  122 _-+ 98  25 •  7 
anti-IL-12 +  IFN-~/  12  58 •  34  12 __- 7  36 --- ll 
IL-12  13  374 "4- 39  3413  --- 1094  99 +  16 
IL-12 +  anti-IFN-~/  13  332  -+ 43  853  --- 243  72 -  29 
anti-IL-12  9  126 -+ 75  37 _+  19  6 •  2 
anti-II-12 +  IFN-~  15  161  __- 50  120 _  33  13 --- 6 
IL-12  23  476 •  20  957 _+ 395  11  •  3 
IL-12 +  anti-IFN-~/  22  430 •  18  1909 •  462  9 •  2 
*Sorted CD4 § CD45RO- and CD8 + CD45RO- peripheral blood lymphocytes were cloned by limiting dilution (PHA stimulation) in the pres- 
ence of the indicated antibodies or cytokines. 
*  T cell clones were expanded for 4 wk in the presence of neutralizing anti-IL-12 mAb (C8.6 ascites, 1:400), anti-IL-12 mAb and recombinant hu- 
man IFN-"/ (1,000 U/m]),  IL-12 (2-5 ng/ml), or lL-12 and neutralizing anti-IFN-3~  mAb (B133.3 ascites, 1:400) as described in Materials and 
Methods. 
~After being expanded for 4 wk, the indicated number of clones was stimulated with anti-CD3 mAb and TPA and production of the indicated cy- 
tokine was measured; results are mean -+ SE of all clones analyzed.  The results are representative  of two experiments with similar data. 
2565  Gerosa et al. ulation with various IFN-~ inducers;  however, when present, 
it increases IFN-'y production, both in IFN-~ producer clones 
and,  at lower levels,  in  non-IFN-~/ producer Th2  clones 
(17, 20). We now find that the priming for high IL-10 pro- 
duction induced by IL-12 has very similar characteristics to 
that  of IFN-~/ production  and  that  IL-10 priming is  in- 
duced when IL-12 is present in the limiting dilution  cul- 
ture in the first 1 or 2 wk and is maintained when cells are 
cultured in the absence of IL-12. As with IFN-% the pres- 
ence  of IL-12  is  not  required  during  stimulation  of the 
clones for IL-10 production, but its presence enhances IL-10 
production.  The time of addition of IL-12 to the limiting 
dilution cultures is also critical: if IL-12 is added at day 0 or 
3,  priming for both  IFN-'y and  IL-10 is  observed;  how- 
ever, if added at day 7 or later, almost no priming effect is 
observed. These results suggest that the clones are suscepti- 
ble to the priming effect of IL-12 in a very narrow tempo- 
ral window during the first few days of clonal expansion. 
IL-12 primes T  cells for IFN-y and IL-10 production in 
a similar fashion, but its ability to induce  acute expression 
of either cytokine is quite different. In freshly isolated PBL, 
IL-12 alone induces IFN-y production and synergizes with 
many other stimuli  (14),  whereas in  the  same conditions, 
no  induction  of IL-10 is  observed,  although  a  more  de- 
tailed analysis of different stimulatory conditions remains to 
be  performed.  However,  a  few  days  of culture  of PBL 
stimulated with PHA or anti-CD3 in the presence oflL-12 
results in high constitutive expression of IL-10, and IL-12 
strongly potentiates the acute production of IL-10 observed 
in  CD4 §  and  CD8 §  T  cell  clones  stimulated  with  anti- 
CD3 antibodies (D. Peritt and G. Trinchieri, manuscript in 
preparation).  Although the mechanism of this priming re- 
mains elusive, it is clearly distinct from that responsible for 
acute IFN-',/and IL-10 production,  which is still  effective 
on advanced or terminally differentiated Thl and Th2 clones 
(17,  20), and is reminiscent of the commitment to a Thl or 
Th2 response in vivo that is observed within a few days af- 
ter immunization (11,  25). 
In  conclusion,  our present  results  and  previous  reports 
indicate  that  IL-12 induces  priming for high  IFN-y  (17) 
and IL-10 production (this article). We also confirm in our 
clonal assay with human T  ceils that IL-4 is required for IL-4 
production  priming  (4).  IL-12  and  IL-4  modulate  each 
other's effect, i.e.,  IL-4 acting at the  clonal level partially 
decreases the priming for high IFN-y production induced 
by IL-12 and very efficiendy prevents the priming for IL-10 
production.  At the clonal level, the ability of IL-12 to in- 
hibit IL-4 production, a striking phenomenon in vivo or in 
polyclonal cultures, is not observed and instead IL-12 en- 
hances  the  ability  of IL-4 to  prime  for  IL-4 production. 
Thus,  similar to  recent  observations in  the  mouse  system 
(25, 55), our results suggest that the IFN-% IL-4, and IL-10 
cytokine  genes  are  independently  regulated  and  that  any 
combination  of these  three  cytokines can be  observed in 
clones generated from human peripheral blood without  a 
clear distinction along the Thl or Th2 phenotype, even when 
the priming effect of IL-12 or IL-4 in vitro is neutralized 
using specific antibodies.  However, when antigen-specific 
clones are generated in vivo or in vitro in polyclonal cul- 
tures,  a  preferential  clustering  of Thl  or Th2-type  cyto- 
kines  is  observed,  both  at  the  polyclonal  and  the  clonal 
level. Because IL-12 and IL-4 do not induce  this dichot- 
omy at the single  cell (or clonal) level in vitro, it is likely 
that the mechanisms leading to the Thl/Th2  polarization 
involve  secondary induced  factors  and/or  selective mecha- 
nisms, which may be influenced by the nature and concen- 
tration  of  the  antigen,  the  APC,  and  other  cytokines 
present at the site of the immune response. However, it is 
striking  that  many of the  clones  obtained  from memory 
human T  cells cultured in the absence of IL-12 and IL-4 (a 
condition  that does not endow  naive CD4  cells  with  the 
ability  to  produce  cytokines)  can  produce  high  levels  of 
one or more of the cytokines IFN-',/, IL-4, and IL-10. The 
pattern of production of these three cytokines appears to be 
stochastic, with no clear polarization of the cells  to a Thl 
or Th2-type phenotype.  Similarly, coexpression of IFN-2t 
and IL-4 was described in a proportion of memory CD4 + T 
cells with the  CD45RO +  or  CD27--  phenotype  (26,  27). 
Because CD4 + T  cells  in those studies were analyzed im- 
mediately after purification from peripheral blood, possible 
artifacts  due  to  the  long-term  cloning  cultures  were  ex- 
cluded.  Note that like the studies  analyzing cytokine  pro- 
duction in fleshly isolated CD4 + peripheral blood when ac- 
tively  stimulated  (26,  27),  our  work  shows  that  clones 
generated from CD4 +  CD45RO-  cells  in the  absence of 
IL-12  or  IL-4  are  unable  to  produce  cytokines,  whereas 
clones generated from CD4 + CD45RO + cells produce  cy- 
tokines  with  a  pattern  reflecting  that  of freshly  isolated 
CD45RO + cells. The cloning procedure in the presence of 
both IL-2 and a polyclonal stimulator, such as PHA, does 
not alter the cytokine profile of the CD4 + cells, thus repre- 
senting a powerful method to study the  role of cytokines 
such as IL-12 during clonal expansion in determining the 
cytokine profile of responding CD4 + T  cells. 
The Th2 cytokine IL-10 has a profound inhibitory effect 
on  the  ability  of phagocytic  cells  to  produce  IL-12  (56), 
and  this  effect may represent  one  of the  mechanisms by 
which  a  Thl  response  is  downregulated  when  Th2-type 
cells  are  activated.  However,  this  simple  interpretation  is 
now complicated by the observation that CD4 + cells pro- 
ducing both IFN-~/ and IL-10 exist in humans and in  the 
mouse  (28,  29),  and can easily be cloned from peripheral 
blood T  cells (this study and 57).  Human T  cell clones pro- 
ducing IFN-~/ and IL-10 have an anti-inflammatory func- 
tion, inhibiting macrophage activation and T  cell prolifera- 
tion (57),  and can be isolated with high frequency from T 
cell populations within the rheumatoid synovial membrane 
(58), where they may be a major contributor to the endog- 
enous  immunosuppression  that  occurs  in  rheumatoid  ar- 
thritis.  Notably high  IFN-'y- and  IL-10-producing clones 
are  induced  by stimulation  with  an  antigenic  peptide  of 
proteolipoprotein,  which  is  mutated  in  the  major TCR- 
interacting residue  and which  protects mice from allergic 
encephahtis induced by the wild-type peptide; these IFN-',/- 
and IL-10-producing clones have an anti-encephalitogenic 
effect in vivo, suggesting that they might represent cell types 
2566  IL-2-induced Priming for IL-10 Production involved in the downregulation of Thl responses (59). The 
CD4 + cell types with unusual cytokine production profiles 
may represent new subsets of Th cells, with effector func- 
tions different from the typical Thl  and Th2 cells and me- 
diating different effects on specific aspects of humoral and/or 
cellular immune  response.  An  alternative interpretation is 
that successful immune responses are characterized by a po- 
larized Thl  or Th2 response, whereas ineffective responses 
resulting in anergy or tolerization may be characterized by 
anomalous cytokine production phenotypes that fall to sus- 
tain an effective cellular or humoral immune response. The 
accumulation of these cell types in the memory compart- 
ment of peripheral blood CD4 + cells may represent the end 
product of unsuccessful or repressed immune responses. In 
particular, the extreme phenotype of high IFN-~/and IL-10 
production  induced  by  IL-12  may  represent  a  cell  type 
with  a  downregulatory  effect  on  Thl  responses,  by  sup- 
pressing expression of IL-12, TNF-ci, IL-113, B7, and other 
costimulatory molecules on APC as well as proliferation of 
Thl  cells (56, 60). 
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